Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC
Shots:
- The P-III (MK-3475A-D77) study assesses Keytruda (SC) with berahyaluronidase alfa (ALT-B4) & CT vs Keytruda (IV) + CT, Q6W, as a 1L treatment of mNSCLC adults
- Study achieved its dual primary PK endpoints, depicting noninferiority in AUC during first dosing cycle & Ctrough at steady state; secondary efficacy & safety results aligned in both treatments. Findings will be highlighted at future conferences & shared with regulatory bodies
- Merck is also conducting a P-III MK-3475A-F84 study (SC vs IV Keytruda for mNSCLC with high PD-L1 expression), P-II MK-3475A-F65 trial (SC Keytruda for r/r Hodgkin lymphoma & primary mediastinal large B-cell lymphoma) & P-II MK-3475A-F11 patient preference study of SC vs IV Keytruda
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
